{
	"code": 200,
	"msg": "Request success",
	"success": true,
	"page": 1,
	"next": 2,
	"count": 1990,
	"limit": 100,
	"data":[
		{"pmid":32124699,"pmcid":"","doi":"10.2174/1568026620666200303123102","title":"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors","authors":"Sabbah DA, Hajjo R, Sweidan K.","journal":"Curr Top Med Chem","year":2020,"if2020":5.123,"citation":"Curr Top Med Chem. 2020;20(10):815-834. doi: 10.2174/1568026620666200303123102.","abstract":"The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation, division, survival, and cancer development. In this review, the EGFR structure and its mutations, signaling pathway, ligand binding and EGFR dimerization, EGF/EGFR interaction, and the progress in the development of EGFR inhibitors have been explored.",
			"citedby": [
				{
					"pmid": "20887192",
					"pmcid": "",
					"doi": "10.1146/annurev-pathol-011110-130206",
					"title": "EGFR mutations and lung cancer",
					"authors": "da Cunha Santos G, Shepherd FA, Tsao MS.",
					"journal": "Annu Rev Pathol",
					"year": "2011",
					"if2020": "7.687",
					"citation": "Annu Rev Pathol. 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206.",
					"abstract": "Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell. Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors. Inhibitors that target the kinase domain of EGFR have been developed and are clinically active. More importantly, such tyrosine kinase inhibitors (TKIs) are especially effective in patients whose tumors harbor activating mutations in the tyrosine kinase domain of the EGFR gene. More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment. Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate. We review the role of EGFR mutations in the diagnosis and management of NSCLC."
				},{
					"pmid": "20887192",
					"pmcid": "",
					"doi": "10.1146/annurev-pathol-011110-130206",
					"title": "EGFR mutations and lung cancer",
					"authors": "da Cunha Santos G, Shepherd FA, Tsao MS.",
					"journal": "Annu Rev Pathol",
					"year": "2011",
					"if2020": "7.687",
					"citation": "Annu Rev Pathol. 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206.",
					"abstract": "Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell. Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors. Inhibitors that target the kinase domain of EGFR have been developed and are clinically active. More importantly, such tyrosine kinase inhibitors (TKIs) are especially effective in patients whose tumors harbor activating mutations in the tyrosine kinase domain of the EGFR gene. More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment. Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate. We review the role of EGFR mutations in the diagnosis and management of NSCLC."
				},{
					"pmid": "20887192",
					"pmcid": "",
					"doi": "10.1146/annurev-pathol-011110-130206",
					"title": "EGFR mutations and lung cancer",
					"authors": "da Cunha Santos G, Shepherd FA, Tsao MS.",
					"journal": "Annu Rev Pathol",
					"year": "2011",
					"if2020": "7.687",
					"citation": "Annu Rev Pathol. 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206.",
					"abstract": "Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell. Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors. Inhibitors that target the kinase domain of EGFR have been developed and are clinically active. More importantly, such tyrosine kinase inhibitors (TKIs) are especially effective in patients whose tumors harbor activating mutations in the tyrosine kinase domain of the EGFR gene. More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment. Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate. We review the role of EGFR mutations in the diagnosis and management of NSCLC."
				},{
					"pmid": "20887192",
					"pmcid": "",
					"doi": "10.1146/annurev-pathol-011110-130206",
					"title": "EGFR mutations and lung cancer",
					"authors": "da Cunha Santos G, Shepherd FA, Tsao MS.",
					"journal": "Annu Rev Pathol",
					"year": "2011",
					"if2020": "7.687",
					"citation": "Annu Rev Pathol. 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206.",
					"abstract": "Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell. Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors. Inhibitors that target the kinase domain of EGFR have been developed and are clinically active. More importantly, such tyrosine kinase inhibitors (TKIs) are especially effective in patients whose tumors harbor activating mutations in the tyrosine kinase domain of the EGFR gene. More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment. Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate. We review the role of EGFR mutations in the diagnosis and management of NSCLC."
				},{
					"pmid": "20887192",
					"pmcid": "",
					"doi": "10.1146/annurev-pathol-011110-130206",
					"title": "EGFR mutations and lung cancer",
					"authors": "da Cunha Santos G, Shepherd FA, Tsao MS.",
					"journal": "Annu Rev Pathol",
					"year": "2011",
					"if2020": "7.687",
					"citation": "Annu Rev Pathol. 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206.",
					"abstract": "Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell. Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors. Inhibitors that target the kinase domain of EGFR have been developed and are clinically active. More importantly, such tyrosine kinase inhibitors (TKIs) are especially effective in patients whose tumors harbor activating mutations in the tyrosine kinase domain of the EGFR gene. More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment. Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate. We review the role of EGFR mutations in the diagnosis and management of NSCLC."
				}
			],
			"similar": [
				{
					"pmid": "29462255",
					"pmcid": "",
					"doi": "10.1093/annonc/mdx704",
					"title": "Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients",
					"authors": "Remon J, Steuer CE, Ramalingam SS, Felip E.",
					"journal": "Ann Oncol",
					"year": "2018",
					"if2020": "5.321",
					"citation": "Ann Oncol. 2018 Jan 1;29(suppl_1):i20-i27. doi: 10.1093/annonc/mdx704.",
					"abstract": "Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. Clinical trials have demonstrated the efficacy of osimertinib in this patient population and clinical trials of other third-generation EGFR TKI are currently under way. Additional challenges in this patient population, such as the upfront efficacy of osimertinib, validation of T790M in liquid biopsies as a dynamic predictive marker of efficacy, along with combination with immune checkpoint inhibitors are being explored, representing an extraordinary time of development for EGFR-mutant NSCLC."
				}
			]},
		{"pmid":28430586,"pmcid":"PMC5564844","doi":"10.18632/oncotarget.16854","title":"Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer","authors":"Liu X, Wang P, Zhang C, Ma Z.","journal":"Oncotarget","year":2017,"if2020":5.123,"citation":"Oncotarget. 2017 Jul 25;8(30):50209-50220. doi: 10.18632/oncotarget.16854.","abstract":"Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal. EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses. Studies have shown that EGFR plays significant roles in the progression of NSCLC. Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage. Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis. We also focus on anti-lung cancer drug development and EGFR-related drug resistance.",
			"similar": [
				{
					"pmid": "29462255",
					"pmcid": "",
					"doi": "10.1093/annonc/mdx704",
					"title": "Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients",
					"authors": "Remon J, Steuer CE, Ramalingam SS, Felip E.",
					"journal": "Ann Oncol",
					"year": "2018",
					"if2020": "5.321",
					"citation": "Ann Oncol. 2018 Jan 1;29(suppl_1):i20-i27. doi: 10.1093/annonc/mdx704.",
					"abstract": "Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. Clinical trials have demonstrated the efficacy of osimertinib in this patient population and clinical trials of other third-generation EGFR TKI are currently under way. Additional challenges in this patient population, such as the upfront efficacy of osimertinib, validation of T790M in liquid biopsies as a dynamic predictive marker of efficacy, along with combination with immune checkpoint inhibitors are being explored, representing an extraordinary time of development for EGFR-mutant NSCLC."
				}
			]
		},
		{"pmid":26996617,"pmcid":"","doi":"10.2174/1389557516666160321114917","title":"Review on EGFR Inhibitors: Critical Updates","authors":"Singh D, Attri BK, Gill RK, Bariwal J.","journal":"Mini Rev Med Chem","year":2016,"if2020":5.123,"citation":"Mini Rev Med Chem. 2016;16(14):1134-66. doi: 10.2174/1389557516666160321114917.","abstract":"Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein that constitutes one of the four members of ErbB family of tyrosine kinase receptors. Activation of EGFR leads to autophosphorylation of receptor tyrosine kinase that initiates a cascade of downstream signaling pathways involved in regulating cellular proliferation, differentiation, and survival. EGFR is abnormally activated by various mechanisms like receptor overexpression, mutation, ligand-dependent receptor dimerization, ligand-independent activation and is associated with the development of variety of human cancers. EGFR inhibition is one of the key targets for cancer chemotherapy. Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of non-small cell lung cancer led to tremendous development of novel EGFR inhibitors in the last decade. Diverse class of chemical compounds from the synthetic origin has been extensively studied. This review highlights the various classes of synthetically derived molecules which have been reported in the last few years as potential EGFR and EGFR/ErbB-2 dual inhibitors. A brief synthetic methodology to access these compounds has been highlighted along with the SAR. We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compounds that inhibit EGFR and ErbB-2."},
		{"pmid":32593400,"pmcid":"","doi":"10.1016/bs.acr.2020.04.003","title":"EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells","authors":"Talukdar S, Emdad L, Das SK, Fisher PB.","journal":"Adv Cancer Res","year":2020,"if2020":5.123,"citation":"Adv Cancer Res. 2020;147:161-188. doi: 10.1016/bs.acr.2020.04.003. Epub 2020 Jun 15.","abstract":"The Epidermal Growth Factor Receptor (EGFR) is frequently expressed at elevated levels in different forms of cancer and expression often correlates positively with cancer progression and poor prognosis. Different mutant forms of this protein also contribute to cancer heterogeneity. A constitutively active form of EGFR, EGFRvIII is one of the most important variants. EGFR is responsible for the maintenance and functions of cancer stem cells (CSCs), including stemness, metabolism, immunomodulatory-activity, dormancy and therapy-resistance. EGFR regulates these pathways through several signaling cascades, and often cooperates with other RTKs to exert further control. Inhibitors of EGFR have been extensively studied and display some anticancer efficacy. However, CSCs can also acquire resistance to EGFR inhibitors making effective therapy even more difficult. To ameliorate this limitation of EGFR inhibitors when used as single agents, it may be of value to simultaneously combine multiple EGFR inhibitors or use EGFR inhibitors with regulators of other important cancer phenotype regulating molecules, such as STAT3, or involved in important processes such as DNA repair. These combinatorial approaches require further experimental confirmation, but if successful would expand and improve therapeutic outcomes employing EGFR inhibitors as one arm of the therapy."},
		{"pmid":24202392,"pmcid":"PMC4049336","doi":"10.1038/nm.3388","title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","authors":"Chong CR, Jänne PA.","journal":"Nat Med","year":2013,"if2020":5.123,"citation":"Nat Med. 2013 Nov;19(11):1389-400. doi: 10.1038/nm.3388. Epub 2013 Nov 7.","abstract":"The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation, division, survival, and cancer development. In this review, the EGFR structure and its mutations, signaling pathway, ligand binding and EGFR dimerization, EGF/EGFR interaction, and the progress in the development of EGFR inhibitors have been explored."},
		{"pmid":18045542,"pmcid":"","doi":"10.1016/j.cell.2007.11.013","title":"SnapShot: EGFR signaling pathway","authors":"Yarden Y, Shilo BZ.","journal":"Cell","year":2007,"if2020":5.123,"citation":"Cell. 2007 Nov 30;131(5):1018. doi: 10.1016/j.cell.2007.11.013.","abstract":"Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal. EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses. Studies have shown that EGFR plays significant roles in the progression of NSCLC. Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage. Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis. We also focus on anti-lung cancer drug development and EGFR-related drug resistance."},
		{"pmid":32510788,"pmcid":"PMC7686272","doi":"10.1002/anie.202003500","title":"Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations","authors":"Jang J, To C, De Clercq DJH, Park E, Ponthier CM, Shin BH, Mushajiang M, Nowak RP, Fischer ES, Eck MJ, Jänne PA, Gray NS.","journal":"Angew Chem Int Ed Engl","year":2020,"if2020":5.123,"citation":"Angew Chem Int Ed Engl. 2020 Aug 17;59(34):14481-14489. doi: 10.1002/anie.202003500. Epub 2020 Jul 9.","abstract":"Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein that constitutes one of the four members of ErbB family of tyrosine kinase receptors. Activation of EGFR leads to autophosphorylation of receptor tyrosine kinase that initiates a cascade of downstream signaling pathways involved in regulating cellular proliferation, differentiation, and survival. EGFR is abnormally activated by various mechanisms like receptor overexpression, mutation, ligand-dependent receptor dimerization, ligand-independent activation and is associated with the development of variety of human cancers. EGFR inhibition is one of the key targets for cancer chemotherapy. Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of non-small cell lung cancer led to tremendous development of novel EGFR inhibitors in the last decade. Diverse class of chemical compounds from the synthetic origin has been extensively studied. This review highlights the various classes of synthetically derived molecules which have been reported in the last few years as potential EGFR and EGFR/ErbB-2 dual inhibitors. A brief synthetic methodology to access these compounds has been highlighted along with the SAR. We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compounds that inhibit EGFR and ErbB-2."},
		{"pmid":9496384,"pmcid":"","doi":"10.1023/a:1008209720526","title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials","authors":"Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS.","journal":"Ann Oncol","year":1997,"if2020":5.123,"citation":"Ann Oncol. 1997 Dec;8(12):1197-206. doi: 10.1023/a:1008209720526.","abstract":"The Epidermal Growth Factor Receptor (EGFR) is frequently expressed at elevated levels in different forms of cancer and expression often correlates positively with cancer progression and poor prognosis. Different mutant forms of this protein also contribute to cancer heterogeneity. A constitutively active form of EGFR, EGFRvIII is one of the most important variants. EGFR is responsible for the maintenance and functions of cancer stem cells (CSCs), including stemness, metabolism, immunomodulatory-activity, dormancy and therapy-resistance. EGFR regulates these pathways through several signaling cascades, and often cooperates with other RTKs to exert further control. Inhibitors of EGFR have been extensively studied and display some anticancer efficacy. However, CSCs can also acquire resistance to EGFR inhibitors making effective therapy even more difficult. To ameliorate this limitation of EGFR inhibitors when used as single agents, it may be of value to simultaneously combine multiple EGFR inhibitors or use EGFR inhibitors with regulators of other important cancer phenotype regulating molecules, such as STAT3, or involved in important processes such as DNA repair. These combinatorial approaches require further experimental confirmation, but if successful would expand and improve therapeutic outcomes employing EGFR inhibitors as one arm of the therapy."},
		{"pmid":18227510,"pmcid":"PMC2538882","doi":"10.1073/pnas.0709662105","title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","authors":"Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ.","journal":"Proc Natl Acad Sci U S A","year":2008,"if2020":5.123,"citation":"Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5. doi: 10.1073/pnas.0709662105. Epub 2008 Jan 28.","abstract":"The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation, division, survival, and cancer development. In this review, the EGFR structure and its mutations, signaling pathway, ligand binding and EGFR dimerization, EGF/EGFR interaction, and the progress in the development of EGFR inhibitors have been explored."},
		{"pmid":28791631,"pmcid":"","doi":"10.1007/978-1-4939-7219-7_1","title":"ErbB Receptors and Cancer","authors":"Wang Z.","journal":"Methods Mol Biol","year":2017,"if2020":5.123,"citation":"Methods Mol Biol. 2017;1652:3-35. doi: 10.1007/978-1-4939-7219-7_1.","abstract":"Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal. EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses. Studies have shown that EGFR plays significant roles in the progression of NSCLC. Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage. Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis. We also focus on anti-lung cancer drug development and EGFR-related drug resistance."}
	]
}